Bioorganic & Medicinal Chemistry Letters 22 (2012) 5297-5302

Contents lists available at SciVerse ScienceDirect

ELSEVIER

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Development of 'DFG-out' inhibitors of gatekeeper mutant kinases

Hwan Geun Choi^{a,d}, Jianming Zhang^{a,d}, Ellen Weisberg^b, James D. Griffin^b, Taebo Sim^{a,c,d}, Nathanael S. Gray^{a,d,*}

^a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

^b Department of Medical Oncology, Dana-Farber Cancer Institute, United States

^c Life Sciences Research Division Korea Institute of Science and Technology (KIST), 39-1, Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Republic of Korea

^d Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 250 Longwood Ave, SGM 628, Boston, MA 02115, USA

ARTICLE INFO

Article history: Received 30 April 2012 Accepted 11 June 2012 Available online 23 June 2012

Keywords: T315I Bcr-Abl Kinase inhibitor Gatekeeper mutant Type II inhibitor Thiazolo[5,4-b]pyridine

ABSTRACT

HG-7-85-01(**22**) and HG-7-86-01(**26**) are thiazolo[5,4-*b*]pyridine containing type II tyrosine kinase inhibitors with potent cellular activity against both wild-type and 'gatekeeper' mutant T315I- Bcr-Abl. Here we report on the 'hybrid design' concept and subsequent structure activity guided optimization efforts that resulted in the development of these inhibitors.

© 2012 Elsevier Ltd. All rights reserved.

Despite the tremendous success of the first generation tyrosine kinase inhibitor imatinib for the treatment of chronic myelogenous leukemia (CML), a portion of the patient population eventually develops resistance.^{1,2} Three 'second generation' inhibitors: nilotinib,³ dasatinib⁴ and bosutinib,⁵ have been approved to treat patients with imatinib resistance however these drugs remain ineffective against T315I 'gatekeeper' mutant form of Bcr-Abl.⁶ A 'third generation' of type II inhibitors that effectively inhibit the T315I Bcr-Abl mutant has recently been developed. These inhibitors include AP24163,7 AP24534,7 DCC-2036,8 BGG463,9 GNF-7,10 DSA series compounds,¹¹ and a series of alkynyl inhibitors,¹² of which only AP24534 and DCC-2036 are reported to be undergoing clinical evaluation. Recently, we described the biological characterization of two Type II tyrosine kinase inhibitors: HG-7-85-01(22)¹³ and HG-7-86-01(**26**)¹⁴ which can potently inhibit the proliferation of cells expressing the major imatinib-resistant gatekeeper T315I-BCR-ABL, T670I-Kit, T674M/I-PDGFRα and mutants T341M/I-Src and which potently and selectively target mutant FLT3. Herein, we describe the hybrid design strategy and medicinal chemistry effort leading to the development of these ATPcompetitive type II inhibitors.

We have previously reported on the use of a rational 'hybriddesign' strategy to convert well known Type I scaffolds into corresponding Type II inhibitors. This approach consists of appending the moiety from a Type II inhibitor that occupies the re-

* Corresponding author. *E-mail address*: nathanael_gray@dfci.harvard.edu (N.S. Gray). gion adjacent to the ATP-binding site created by the flip of the 'DFG-motif' to the portion of a Type I inhibitor that makes contacts with the hinge region of the kinase.¹⁵ We designed the thiazolopyridine tyrosine kinase inhibitors reported here by hybridizing the hinge interacting thiazole functionality of the Type I inhibitor dasatinib with the 3-trifluoromethylbenzamide pharmacophore present in Type II inhibitors such as imatinib, nilotinib and sorafenib.

The first hybrid compounds that we designed are exemplified by HG-7-85-01 (22) and HG-7-86-01 (26) and contain a thiazolopyridine core, a 3-trifluoromethylbenzamide Type II 'tail' and various groups appended to the thiazolopyridine (Fig. 1). The synthesis of the thiazolo[5,4-b]pyridine core commenced with a Suzuki coupling between commercially available 2-chloro-5-nitropyridine and various phenylboronic acids (Scheme 1). The nitro group was reduced using 5% Pd/C and the resulting product was readily brominated using N-bromosuccinimide at low temperature. One-pot 2-(methylthio)thiazole formation was accomplished using potassium ethyl xanthogenate and iodomethane to yield compound 5. The sulfide group was oxidized with oxone to sulfone compound **6** which could be easily displaced using ammonia in isopropanol. Saponification of ester compound 8 followed by amide coupling using HATU and DIEA provided the target compound 9a.

The synthesis of compounds **10–13** was accomplished by acylation or amidation of the NH₂ moiety in **9a**. Urea formation to form **14** was accomplished via acylation of **9a** with 4-nitrophenyl chloroformate followed by displacement of the 4-nitrophenyl

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter @ 2012 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.bmcl.2012.06.036



New Type II inhibitors

Figure 1. Design rational for the thiazolopyridine scaffold.



Scheme 1. Reagent and conditions: (a) boronic acids[(3-(ethoxycarbonyl)phenylboronic acid($R_1 = H$), 5-methoxycarbonyl-2-methylphenylboronic acid ($R_1 = H$), 5-ethoxycarbonyl-2-fluorophenylboronic acid ($R_1 = F$)], Pd(PPh₃)₂Cl₂, *tert*-butyl XPhos, 2N Na₂CO₃(aq), dioxane, 90 °C, 10 h; (b) 5% Pd/C, EtOH, 16 h; (c) NBS, DMF, 0 °C, 5-10 min; (d) potassium ethyl xanthogenate, AcOH, NMP, 150 °C, 16 h and Mel, 50 °C, 30 min; (e) Oxone, MeOH, THF, Water, rt, 16 h; (f) 2.0 N NH₃ in IPA, 90 °C, 24 h; (g) LiOH·H₂O, THF, MeOH, H₂O, rt, 16 h; (h) HATU, DIEA, 3-(trifluoromethyl)aniline, DMF, rt, 16 h.

group with 4-amino-1-Boc-piperidine. The aryl/heteroaryl substituted compounds **15–16** were achieved by palladium catalyzed coupling reactions between **9a** and the appropriate aryl halide and protecting group manipulations.

Table 1

Cellular antiproliferative activity of compounds **9a-16**





^a Cellular antiproliferative activity (EC₅₀, μ M) on wt Bcr-Abl-Ba/F3.

 $^{b}\,$ Cellular antiproliferative activity (EC_{50}, $\mu M)$ on mutant Bcr-Abl-T315I-Ba/F3.

^c Cytotoxicity (EC₅₀, µM) on wt-Ba/F3.

To evaluate the ability of the compounds to inhibit Bcr-Abl in a cellular context we used the murine pre-B cell line Ba/F3 transformed with the Bcr-Abl oncogene. Wild-type Ba/F3 cells proliferate only in the presence of interleukin-3 (IL-3) while Ba/F3 cells transformed with oncogenic kinases such as Bcr-Abl become capable of growing in the absence of IL-3. This provides a robust and commonly used assay for selective kinase inhibition.¹⁶ The smallest compound 9a did not display antiproliferative activity against wild-type Bcr-Abl or T315I-Bcr-Abl and the larger compounds 12-16 possessed only weak anti-proliferative activity effect (Table 1). Interestingly, only one compound containing a small cyclopropyl amide displayed submicromolar antiproliferative activity against Bcr-Abl and T315I-Bcr-Abl. Compound 11 exhibited EC₅₀'s of 420 nM on wild-type Bcr-Abl and 960 nM onT315I-Bcr-Abl; however 11 also showed a similar antiproliferative effect against parental Ba/F3 cells suggesting that targets other than Bcr-Abl may contribute to the antiproliferative activity of this compound. To explore this chemical series further we next prepared compounds **20-23** which possess an extended Type II tail containing an (4-ethyl-piperazin-1-yl)methyl moiety appended to the 4-position of the trifluoromethylbenzamide (Table 2). This chemical maneuver resulted in an approximate 6-fold improvement in cellular antiproliferative activity relative to 11 against T315I-Bcr-Abl and a 3-fold decrease in cytotoxicity against parental Ba/F3 cells (Table 2, compound 22).

We hypothesized that an intramolecular interaction between the thiazole sulfur and the oxygen atom of the adjacent amide in

Table 2

SAR of non-bonded sulfur and oxygen(nitrogen) interaction derivatives



Compd	R ₃	Cellular antiproliferative activity (EC $_{\rm 50}$, $\mu M)$			
		Bcr-Abl (wt)	Bcr-Abl (T315I)	BaF3	
20 21 22	H Acetyl Cyclopropagecarbogyl	>10 0.139 3.085	>10 0.193 0.156	>10 4.16 3.085	
23	2-Pyridinyl	0.146	0.276	3.532	



Figure 2. Compound **22** (turquois sticks) forms five hydrogen-bonding interactions with Src; (A) Two hydrogen bonds are made with the hinge region: between the thiazole N and backbone NH of M341 and between the cyclopropyl amide NH and the backbone carbonyl of M341. (B) Hydrogen bonding interactions exist between the benzamide carbonyl of 22 and the backbone NH of D404 of the DFG-motif, between the benzamide NH and side-chain carboxylate of E310 from the α C-helix, and from the presumably protonated distal piperazine nitrogen and the backbone carbonyls of V383 and H384.

compounds **21–22** contributes to their conformation and biological activity.¹⁷ This is supported by the similar cellular potencies of **21–22** with the 2-pyridine derivative **23**. Compound **23** is predicted to exhibit a similar bioactive conformation to **21–22** as a result of a lone pair of electrons from the pyridine N interacting with the unfilled orbitals of the thiazole sulfur as shown by previous computational analysis.¹⁸ Finally we established the bioactive conformation of this series of compounds by elucidation of a co-crystal structure

Table 3

Cellular antiproliferation activity of analogs 24-33

Compd	Structure	Cellular antiproliferative activity (EC $_{50}$, μM)		
		Bcr-Abl (wt)	Bcr-Abl (T315I)	BaF3
24	HN S N H CF3	2.31	2.30	2.30
25		>10	>10	>10
26	HN - S - N - HN - S - N - H - N - N - N - N - N - N - N - N	0.38	0.19	1.99
27	HN S N H CF3 N	0.001	0.06	1.23
28		0.03	0.56	4.67
29		0.02	0.30	>10
30	HN S N H H H N H	0.02	0.59	>10
31	HN-S-N-H O CF ₃ -N-	0.2	0.78	>10
32	$H_{N} \xrightarrow{N} H_{N} \xrightarrow{H} H_{N} \xrightarrow{H} H_{N} \xrightarrow{CF_{3}} N$	0.018	0.013	0.69
33	HN S N H H H CF3	1.24	0.55	>10

between HG-7-85-01(**22**) and Src (Fig. 2, PDB code: 4AGW). The structure revealed that the distance between the sulfur and oxygen is 2.7 Å which is shorter than the sum of the normal oxygen and sulfur van der Waals radii of 3.3 Å. Consistent with the 'hybrid-de-sign' strategy, compound **22** was confirmed to bind to the DFG-out 'inactive' conformation of Src.¹¹

We next further explored substitution on the 3-trifluorophenyl moiety which occupies the pocket created by the 'DFG-out' flip of the activation loop (Table 3 and **24–26**). Compound **24**, which eliminates the methylene spacer between the aryl group and

piperazine in **22**, lost approximately 10-fold cellular activity relative to **22**. Compound **25** lacking the CF₃ group was completely inactive up to the highest concentration tested (10μ M). Compound **26**, which possesses the 'tail' moiety of nilotinib exhibited slightly diminished potency relative to compound **22** but substantially improved the overall kinase selectivity as demonstrated below. We next explored the effects of introducing a flag-methyl or 2-fluoro onto the central phenyl ring (Table 3and **27–30**). The compounds exhibited enhanced activity on Bcr-Abl but not on T315I-Bcr-Abl. For example, compound **27** is an exceptionally potent as

A. General synthetic route for Table 1



B. General synthetic route for reverse amide and urea compounds



Scheme 2. Reagent and conditions; (A) (a) acyl chloride, pyridine, DCM, 0 °C, 4 h or acid, EDCI, HOBT, DMAP, DMF, rt, 8 h, (b) i. 4-nitrophenyl chloroformate, pyridine, DCM, rt, 1 h, (ii) *tert*-butyl 4-aminopiperidine-1-carboxylate, TEA, THF, rt, 4 h, (iii) TFA, DCM, 4 h, (c) (i) *tert*-butyl 4-(6-chloro-2-methylpyrimidin-4-yl)piperazine-1-carboxylate, Pd₂(dba)₃, Xanthphos, K₂CO₃, 2-BuOH, 90 °C, 4 h, (ii) TFA, DCM, 4 h; (B) (a) Cyclopropanecarbonyl chloride, pyridine, DCM, 0 °C, 4 h, (b) TFA, DCM, 4 h, (c) (i) benzoic acid, HATU, DIEA, DMF, 16 h. or *tert*-butyl 4-aminopiperidine-1-carboxylate, TEA, THF, rt, 4 h.



Figure 3. Kinase Selectivity of HG-7-85-01(22) and HG-7-86-01(26).

inhibitor of wild-type Bcr-Abl dependent Ba/F3 cell proliferation. We also investigated the effect of reversing the amide between the central phenyl and CF_3 -substituted ring and replacing the amide with a urea moiety. The synthesis of these compounds is de-

picted in Scheme 2B. Reversing the amide bond orientation, compound **33** compared to **22**, resulted in approximately a fourfold reduction in cellular activity against T315I-Bcr-Abl. Interestingly, introduction of a urea linkage (**32**) resulted in 5- to 10- fold

Table 4	
Pharmacokinetic results following intravenous 1 mg/kg and oral 2 mg/k	g dosing

Compd	Route of administration	$t_{1/2}$ (h)	$T_{\rm max}$	C_{\max} (ng/ml)	AUC (min*ng/ml)	AUC (%extrapolated)	Cl (ml/min/kg)	MRT (h)	VSS (L/kg)	%F
22	РО	4.7	2.7	53.1	27733	35	74.4	7.7		18.8
	IV	5.8	0.08	291.7	73800	35.3	13.7	8.1	6.5	
26	PO	3.7	1.1	32.0	8160	21	303.3	5.3		3.7
	IV	2.4	0.14	671.7	111167	8.7	9.5	3.1	1.7	

improved activity on both wild-type and T315I Bcr-Abl, but increased cytotoxicity towards parental Ba/F3 cells by approximately fivefold.

The kinase selectivity of HG-7-85-01(**22**) and HG-7-86-01(**26**) was evaluated using the KINOMEscanTM approach (Ambit Biosciences, San Diego, CA) against a panel of 353 kinases at a concentration of 10 μ M.¹⁹ The kinases which interacted with **22** and **26** with an Ambit score less than 10% of the DMSO control are highlighted with a red circle in a spot tree (Fig. 3, Supplementary data contains full screening data for **22** and **26**). To provide a measure of overall kinase selectivity we calculated S(10) scores, which is defined as the ratio of the number of kinases inhibited below a score of ten versus total number of kinases tested at a specified concentration. This analysis revealed that compound **26** possess an S(10) of 0.36 and compound **22** possesses an S(10) of 0.10 at a concentration of 10 μ M.

We assessed the pharmacological properties of compound **22** and **26** in rats following oral and intravenous delivery (Table 4) prior to performing the murine tumor models which we have previously reported.¹³ HG-7-85-01(**22**) has limited oral bioavailability (%*F* = 18.8), a moderate half-life ($T_{1/2}$ = 5.8 h), a relatively low maximal serum concentration (C_{max} = 292 ng/mL at 2 mg/kg) and a relatively high clearance (Cl = 13 ml/min/kg). HG-7-86-01(**26**) has poor oral bioavailability (%*F* = 4.7), however has better exposure as indicated by AUC (111167 min*ng/ml).

In summary, we have used a rational hybrid-design approach to design a new type II scaffold by combining functionality from the type I inhibitor dasatinib with moieties from the type II inhibitors imatinib, nilotinib and sorafenib. The compounds such as **22** and **26** are capable of potently inhibiting wild-type and T315I-Bcr-Abl activity in biochemical and cellular assays. Further optimization of this scaffold for inhibition of Bcr-Abl and other potential targets identified by the kinase profiling are currently on-going.

Acknowledgment

We thank Nam Doo Kim for assistance with molecular modeling and Sara Buhrlage for critical reading of the manuscript. We acknowledge research funding from Novartis and NIH (R01 CA130876-02).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bmcl.2012. 06.036.

References and notes

- 1. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. *Nat. Med.* **1996**, *2*, 561.
- Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta, D. J.; Reese, S. F.; Ford, J. M.; Capdeville, R.; Talpaz, M. N. *Engl. J. Med.* 2001, 344, 1038.
- Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. *Cancer Cell* **2005**, *7*, 129.
- Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Science 2004, 305, 399.
- Puttini, M.; Coluccia, A. M.; Boschelli, F.; Cleris, L.; Marchesi, E.; Donella-Deana, A.; Ahmed, S.; Redaelli, S.; Piazza, R.; Magistroni, V.; Andreoni, F.; Scapozza, L.; Formelli, F.; Gambacorti-Passerini, C. *Cancer Res.* **2006**, *66*, 11314.
- O'Hare, T.; Walters, D. K.; Deininger, M. W.; Druker, B. J. Cancer Cell 2005, 7, 117.
- O'Hare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T.; Huang, W.-S.; Xu, Q.; Metcalf, C. A., 3rd; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W. N.; Druker, B. J.; Clackson, T. *Cancer Cell* **2009**, *16*, 401.
- Eide, C. A.; Adrian, L. T.; Tyner, J. W.; MacPartlin, M.; Anderson, D. J.; Wise, S. C.; Smith, B. D.; Petillo, P. A.; Flynn, D. L.; Deininger, M. W. N.; O'Hare, T.; Druker, B. J. *Cancer Res.* **2011**, *71*, 3189.
- 9. Program of the Fall Meeting 2008. CHIMIA International Journal for, Chemistry 2008, 62(7-8), pp 547-557.
- Choi, H. G.; Ren, P.; Adrian, F.; Sun, F.; Lee, H. S.; Wang, X.; Ding, Q.; Zhang, G.; Xie, Y.; Zhang, J.; Liu, Y.; Tuntland, T.; Warmuth, M.; Manley, P. W.; Mestan, J. R.; Gray, N. S.; Sim, T. J. Med. Chem. 2010, 53, 5439.
- 11. Seeliger, M. A.; Ranjitkar, P.; Kasap, C.; Shan, Y.; Shaw, D. E.; Shah, N. P.; Kuriyan, J.; Maly, D. J. *Cancer Res.* **2009**, 69, 2384.
- Deng, X.; Lim, S. M.; Zhang, J.; Gray, N. S. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 4196.
 Weisberg, E.; Choi, H. G.; Ray, A.; Barrett, R.; Zhang, J.; Sim, T.; Zhou, W.;
- Weisberg, E.; Choi, H. G.; Ray, A.; Barrett, R.; Zhang, J.; Sim, T.; Zhou, W.; Seeliger, M.; Cameron, M.; Azam, M.; Fletcher, J. A.; Debiec-Rychter, M.; Mayeda, M.; Moreno, D.; Kung, A. L.; Janne, P. A.; Khosravi-Far, R.; Melo, J. V.; Manley, P. W.; Adamia, S.; Wu, C.; Gray, N.; Griffin, J. D. Blood **2010**, *115*, 4206.
- Weisberg, E.; Choi, H. G.; Barrett, R.; Zhou, W.; Zhang, J.; Ray, A.; Nelson, E. A.; Jiang, J.; Moreno, D.; Stone, R.; Galinsky, I.; Fox, E.; Adamia, S.; Kung, A. L.; Gray, N. S.; Griffin, J. D. *Mol. Cancer Ther.* **2010**, *9*, 2468.
- Okram, B.; Nagle, A.; Adrian, F. J.; Lee, C.; Ren, P.; Wang, X.; Sim, T.; Xie, Y.; Xia, G.; Spraggon, G.; Warmuth, M.; Liu, Y.; Gray, N. S. Chem. Biol. 2006, 13, 779.
- Melnick, J. S.; Janes, J.; Kim, S.; Chang, J. Y.; Sipes, D. G.; Gunderson, D.; Jarnes, L.; Matzen, J. T.; Garcia, M. E.; Hood, T. L.; Beigi, R.; Xia, G.; Harig, R. A.; Asatryan, H.; Yan, S. F.; Zhou, Y.; Gu, X. J.; Saadat, A.; Zhou, V.; King, F. J.; Shaw, C. M.; Su, A. I.; Downs, R.; Gray, N. S.; Schultz, P. G.; Warmuth, M.; Caldwell, J. S. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 3153.
- 17. Nagao, Y.; Hirata, T.; Goto, S.; Sano, S.; Kakehi, A.; Iizuka, K.; Shiro, M. J. Am. Chem. Soc. **1998**, 120, 3104.
- Bilodeau, M. T.; Rodman, L. D.; McGaughey, G. B.; Coll, K. E.; Koester, T. J.; Hoffman, W. F.; Hungate, R. W.; Kendall, R. L.; McFall, R. C.; Rickert, K. W.; Rutledge, R. Z.; Thomas, K. A. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 2941.
- Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Nat. Biotechol. 2011, 29, 1046.